{"id":917075,"date":"2025-12-07T11:03:03","date_gmt":"2025-12-07T16:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/"},"modified":"2025-12-07T11:03:03","modified_gmt":"2025-12-07T16:03:03","slug":"dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/","title":{"rendered":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET"},"content":{"rendered":"
\n

WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc<\/a>. (Nasdaq: DYN), a clinical-stage company focused\u00a0on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort\u00a0(REC)\u00a0of the\u00a0Phase 1\/2 DELIVER trial of\u00a0zeleciment\u00a0rostudirsen\u00a0(z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.<\/p>\n

\n Investor Conference Call and Webcast<\/strong>
\n
The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the webcast and replay, please visit\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations<\/a>.<\/p>\n

\n About Dyne Therapeutics<\/strong>\n <\/p>\n

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https:\/\/www.dyne-tx.com\/<\/a>\u00a0and follow us on\u00a0X<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0Facebook<\/a>.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Mia Tobias
ir@dyne-tx.com<\/a>
<\/a>781-317-0353<\/p>\n

\n Media<\/strong>
\n
Stacy Nartker
snartker@dyne-tx.com<\/a>
781-317-1938<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused\u00a0on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort\u00a0(REC)\u00a0of the\u00a0Phase 1\/2 DELIVER trial of\u00a0zeleciment\u00a0rostudirsen\u00a0(z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide … <\/p>\n

Continue reading “Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917075","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused\u00a0on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort\u00a0(REC)\u00a0of the\u00a0Phase 1\/2 DELIVER trial of\u00a0zeleciment\u00a0rostudirsen\u00a0(z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide … Continue reading "Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-07T16:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET\",\"datePublished\":\"2025-12-07T16:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/\",\"name\":\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=\",\"datePublished\":\"2025-12-07T16:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - Market Newsdesk","og_description":"WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused\u00a0on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort\u00a0(REC)\u00a0of the\u00a0Phase 1\/2 DELIVER trial of\u00a0zeleciment\u00a0rostudirsen\u00a0(z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide … Continue reading \"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-07T16:03:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET","datePublished":"2025-12-07T16:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/"},"wordCount":290,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/","name":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=","datePublished":"2025-12-07T16:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODExOCM3MzA5OTA5IzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-topline-results-from-registrational-expansion-cohort-rec-of-deliver-clinical-trial-of-z-rostudirsen-dyne-251-in-duchenne-mu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917075"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917075\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}